Shareholders to Vote on Massive 20x Increase in Authorized Shares to Fund Operations Amid Going Concern Warning

summarizeSummary

BioRestorative Therapies filed a definitive proxy statement for a special meeting to vote on increasing authorized common stock from 75 million to 1.5 billion shares, a critical step for future capital raises amid going concern and delisting warnings.

check_boxKey Events · Corporate Governance and Compliance · BRTX

• Definitive Proxy Filed for Special Meeting

  The company filed a definitive proxy statement (DEF 14A) for a special meeting of stockholders to be held on May 26, 2026, formalizing the proposals previously outlined in a preliminary filing on April 3, 2026.

• Massive Increase in Authorized Shares Proposed

  Shareholders will vote on amending the company's charter to increase the number of authorized common stock from 75,000,000 to 1,500,000,000 shares, a 20-fold increase.

• Significant Potential Dilution

  With 25,478,170 shares currently outstanding, if all authorized shares were issued, dilution would be over 5700%, significantly impacting existing shareholder ownership.

• Capital Raise Critical for Going Concern

  The company states the additional authorized shares are necessary to provide flexibility for future capital raises to fund clinical trials, research, and general corporate purposes, directly addressing its 'substantial doubt about its ability to continue as a going concern' and a Nasdaq delisting notice.

auto_awesomeAnalysis · BRTX · Industrial Applications And Services

BioRestorative Therapies, a nano-cap company facing a Nasdaq delisting notice and a 'going concern' warning, has filed a definitive proxy statement for a special meeting on May 26, 2026. The primary proposal seeks shareholder approval to increase authorized common stock from 75 million to 1.5 billion shares, a 20-fold increase. This follows a preliminary proxy filing on April 3, 2026. The company explicitly states this increase is intended to provide flexibility for future capital raises to fund clinical trials, research, and general corporate purposes. With 25,478,170 shares currently outstanding, if all newly authorized shares were issued, potential dilution would be over 5700%. While highly dilutive, this move is presented as critical for the company's ability to secure necessary financing and continue operations, addressing its precarious financial position and the Nasdaq minimum bid price requirement.